ICON Partners with iCardiac On Phase I


Applied Clinical Trials

ICON announced that its clinical research unit in San Antonio is a certified and preferred site in iCardiac’s Early Precision QT Program. The certification enables ICON to offer iCardiac’s Early Precision QT® services for evaluating the cardiac safety of new compounds in Phase I clinical trials. More accurate early QT studies may eliminate the need for later stage TQT studies, potentially saving costs.

Read the full release.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.